PKU HealthCare (SZ:000788) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-08-12 00:50Background Overview - The company, Peking University Medicine Co., Ltd., has a long-term service contract with Peking University International Hospital for the supply and distribution of medical equipment, surgical instruments, drugs (excluding special drugs), in vitro diagnostic reagents, and medical consumables, which was approved in April and May 2022. The contract is valid for three years [1]. Progress Update - The company received notification in November 2024 that the long-term service contract with the International Hospital will end in May 2025, and a bidding process for the supply of in vitro diagnostic reagents and medical consumables will be initiated, inviting the company to participate [2]. - Following the termination of the business cooperation in May 2025, the company's subsidiary, North Medical Medicine, will face a complete halt in its main business operations starting June 2025, as it has not found similar business opportunities. This situation may lead to significant operational challenges, including personnel restructuring and potential business transformation [3]. Financial Impact - The company anticipates a revenue decrease of approximately 600 million yuan (29.13% of the latest audited revenue) and a net profit reduction of about 40 million yuan (28.99% of the latest audited net profit attributable to shareholders) from June 2025 to the end of that year. Furthermore, from 2026 onwards, the expected revenue decline could reach about 1.027 billion yuan (49.85% of the latest audited revenue) and a net profit decrease of approximately 68.69 million yuan (49.78% of the latest audited net profit attributable to shareholders) [3].